DURHAM, N.C., Oct. 12, 2018 /PRNewswire/ -- NeuroCog Trials announced today that they are changing their name to VeraSci and have rebranded all of their materials and website to better represent their current position as comprehensive collaborative partners in scientific discovery. They are also merging NeuroCog Trials with NCT Linguistics, formerly a division of NeuroCog Trials, under the VeraSci brand. The name change was driven by the company's expansion into new therapeutic areas, their larger global and language footprints, and the broadening of the scope of services and technology they provide as partners to industry, academic and government programs. To support this vital new brand, they have launched www.VeraScience.com, a dynamic website that reflects their new branding while showcasing the full depth and breadth of their expanded offerings and progressive movement into new areas of expertise.
Caren Gadigian, President at VeraSci, stated, "Over the 14 years since our inception, we have expanded our areas of expertise and innovation to include a variety of clinical and regulatory endpoints over a range of human disorders and diseases. We have also developed a multitude of technological advances that are changing the way human assessment is conducted in clinical research across the world."
The Evolution from NeuroCog Trials to VeraSci
When first incorporated in 2004, NeuroCog Trials focused primarily on the development and support of cognitive endpoints for clinical trials. In response to frequent sponsor requests, over time they have amplified their expertise to include areas such as mood disorders, movement disorders, psychosis, oncology and rare and orphan diseases. Due to their increased participation in trials outside the US, their language service offerings have also grown. Today, they specialize in translation, localization, interpretation and training in over 150 different languages and provide language services worldwide.
Throughout this growth, they have continually kept their finger on the pulse of technological advancements in and around the pharmaceutical industry. Through the VeraSci Innovation Lab, their scientists and technicians fuse next-generation technology with data collection into many of their proprietary eCOA tools, all of which are easily configured to best meet the needs of any study.
"Given these exciting developments, and our new collaborations with partners in technology and medicine," stated Dr. Richard Keefe, VeraSci CEO, "we wanted our name to reflect the broad range of our new activities as well as our ongoing commitment to our foundational principles of scientific integrity and true signal identification in the noisy real-world environment of clinical trials research."
Founded in 2004, VeraSci has a worldwide presence in clinical trial support, clinical and cognitive assessment, and language services. The company offers a robust platform of products and services that positions them as an ideal research partner anywhere on the globe. VeraSci's areas of expertise have continually expanded and grown since inception, allowing them to offer validated full-service solutions to clients. VeraSci brings deep expertise, strategic innovation and unwavering commitment to each and every client and project, allowing them to deliver data supporting innovative therapies to reduce suffering.
VeraSci and NeuroCog Trials are registered trademarks of NCT Holdings in the United States and/or other countries.Founded in 2004 as NeuroCog Trials (NCT), VeraSci is a privately held, certified woman-owned business, headquartered in Durham, North Carolina.